{"id":"W2911465702","doi":"10.1016/s1470-2045(18)30898-2","title":"Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Foundation for Research on Metabolic Disorders; Cancer Research UK; Ironwood Pharmaceuticals, Incorporated; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Clinical endpoint; Placebo; Quality of life (healthcare); Internal medicine; Discontinuation; Oncology; Prostate-specific antigen; Clinical trial; Visual analogue scale; Cancer; Physical therapy; Pathology; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002633119,0.002203105,0.004250787,0.0005031164,0.000543386,0.001031771,0.00100386,0.002397349,0.007145677],"category_scores_gemma":[0.002601729,0.0007129731,0.003672357,0.0004384168,0.001300074,0.001204428,0.0006517718,0.003613171,0.0009467085],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007425025,"about_ca_system_score_gemma":0.000902561,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001656964,"about_ca_topic_score_gemma":0.003017837,"domain_scores_codex":[0.9987717,0.0008171019,0.00006981717,0.0001566061,0.0000614089,0.0001233018],"domain_scores_gemma":[0.9987375,0.0004462336,0.0003734047,0.00009164283,0.00008442823,0.0002667939],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9882026,0.001008698,0.0003384355,0.001245397,0.001615354,0.00002140499,0.00004084951,0.0002226069,0.000586395,0.00006362401,0.0005558843,0.006098788],"study_design_scores_gemma":[0.972185,0.02394792,0.001954076,0.00007476397,0.0008650667,0.00002048308,0.00002196902,0.0001738089,0.0001328286,0.0001261777,0.0004817093,0.00001630629],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9564466,0.02840616,0.00102504,0.001254134,0.001292743,0.003881731,0.003621078,0.0002618424,0.00381067],"genre_scores_gemma":[0.9803112,0.007086429,0.001647827,0.001278536,0.0007146338,0.003531756,0.001720673,0.00003994259,0.003669013],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007145677,"threshold_uncertainty_score":0.02390468,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07290594750234178,"score_gpt":0.4120982191664367,"score_spread":0.3391922716640949,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}